Every few years, a clinical trial result arrives that genuinely reshapes a field. The Phase 2 data for retatrutide (LY3437943), published in the New England Journal of Medicine in June 2023, was one of those moments. A 48-week randomized controlled trial showed that the highest dose of retatrutide produced a mean body weight reduction of 24.2% — a number that, to put it in perspective, approaches the weight loss outcomes seen with bariatric surgery.[1]

Understanding the Triple Mechanism

To understand why retatrutide performs so differently from its predecessors, it helps to understand what it targets. Retatrutide is a once-weekly subcutaneous injection that simultaneously activates three distinct receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).

Each receptor contributes a distinct metabolic effect. GLP-1 receptor agonism — the mechanism shared with semaglutide — reduces appetite, slows gastric emptying, and improves insulin secretion. GIP receptor agonism — the mechanism shared with tirzepatide — amplifies the GLP-1 effect, improves insulin sensitivity, and may reduce the nausea associated with GLP-1 agonism alone. The third target, the glucagon receptor, is what makes retatrutide unique: glucagon receptor agonism increases energy expenditure by stimulating fat oxidation in the liver, raises basal metabolic rate, and promotes the breakdown of stored fat.[1][2]

This triple mechanism creates a synergistic effect that is greater than the sum of its parts. While GLP-1 agonism reduces caloric intake and GIP agonism improves metabolic efficiency, glucagon receptor agonism increases the rate at which stored fat is burned — addressing both sides of the energy balance equation simultaneously.

The Phase 2 NEJM Data: What Was Actually Found

The Phase 2 trial enrolled 338 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, without type 2 diabetes. Participants were randomized to one of five retatrutide doses (1 mg, 4 mg, 8 mg, or 12 mg weekly) or placebo for 48 weeks.[1]

The results were remarkable across all active doses. At the highest dose (12 mg), participants lost a mean of 24.2% of their body weight at 48 weeks. At 8 mg, the mean weight loss was 22.8%. Even at the 4 mg dose, participants lost a mean of 17.5% of body weight. The placebo group lost 2.1%.[1] To contextualize these numbers: semaglutide 2.4 mg (Wegovy) produces approximately 15% mean weight loss at 68 weeks; tirzepatide 15 mg (Zepbound) produces approximately 22.5% at 72 weeks. Retatrutide appears to achieve comparable or superior results in a shorter timeframe.

Critically, the weight loss trajectory had not plateaued at 48 weeks in the higher-dose groups, suggesting that longer-term trials may show even greater reductions. Phase 3 trials (TRIUMPH program) are currently underway.

Cardiometabolic Effects Beyond Weight

Weight loss was not the only significant finding. The trial also documented meaningful improvements in cardiometabolic markers. Participants in the active treatment groups showed significant reductions in waist circumference, blood pressure, triglycerides, and fasting glucose, along with improvements in HDL cholesterol.[1] These improvements are consistent with the known effects of GLP-1 and GIP receptor agonism on metabolic health, amplified by the additional glucagon receptor component.

A 2024 analysis of the Phase 2 data specifically examining liver fat found that retatrutide produced substantial reductions in hepatic fat content — a finding with significant implications for the large proportion of patients with obesity who also have non-alcoholic fatty liver disease (NAFLD).[2]

Safety Profile and Tolerability

The safety profile of retatrutide in Phase 2 was broadly consistent with the GLP-1 class. The most common adverse events were gastrointestinal — nausea, vomiting, diarrhea, and constipation — and were most frequent during the dose-escalation period. The majority were mild to moderate in severity and resolved over time. Discontinuation due to adverse events occurred in 16% of participants at the highest dose, compared to 2% in the placebo group.[1]

One finding of note was a modest increase in heart rate (approximately 5–7 beats per minute at higher doses), consistent with the glucagon receptor component of the mechanism. This is a known effect of glucagon receptor agonism and is being monitored carefully in Phase 3 trials.

Where Retatrutide Fits in Clinical Practice

Retatrutide is not yet FDA-approved and remains in Phase 3 clinical trials as of 2026. It represents the leading edge of a new generation of metabolic medications that target multiple receptor systems simultaneously to achieve outcomes that single-mechanism agents cannot match. For patients who have not achieved their goals with semaglutide or tirzepatide, or for whom a more aggressive metabolic intervention is appropriate, retatrutide — once approved — may represent a meaningful advancement.

At Nectar Wellness, we follow the clinical development of emerging metabolic therapies closely and are committed to offering our patients access to the most current and evidence-based options available. Our clinical team can discuss your individual metabolic health goals and help determine which approach is most appropriate for your situation.

"Retatrutide produced substantial, dose-dependent reductions in body weight, with the highest dose achieving a mean weight loss of 24.2% at 48 weeks — results with no precedent in the history of obesity pharmacology." — Jastreboff et al., New England Journal of Medicine, 2023